A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

ReddyPort™ Elbow Non-Invasive Ventilation Product Receives CE Mark Approval

ReddyPort, a medical technology company focused on solutions that enable better care experiences for patients on non-invasive ventilation (NIV), announced today that it has received Conformité Européene (CE) Mark approval for ReddyPort™ Elbow.

The CE marking confirms that ReddyPort, a suite of solutions that promotes NIV success, and allows clinicians to perform procedures through the ventilation mask without interrupting therapeutic pressure meets the requirements of the European Medical Devices Directive (MDD). This now allows ReddyPort to commercialize ReddyPort™ Elbow across the European Union and other CE Mark geographies.

“CE Mark is an important milestone and validation of our vision to make ReddyPort the standard of care for patients on NIV,” said Scott Bostick, chief executive officer of ReddyPort. CE Mark approval means we can help patients in Europe who struggle tolerating NIV therapy due to known issues while wearing the mask; dry-mouth, phlegm build-up, and difficulty communicating. ReddyPort™ Elbow and oral care products help improve tolerance, patient compliance, and comfort, leading to more successful NIV. Supporting a successful NIV is especially important now as clinicians need it most during the COVID-19 pandemic.”

NIV is the first line of therapy in respiratory insufficiency or failure, commonly seen with COPD, CHF, asthma, pneumonia or ARDS1. NIV intolerance can lead to failure and escalation of care with mechanical ventilation. ReddyPort products promote NIV success, by empowering clinicians and patients with simplified oral access without interrupting patient therapy.

ReddyPort features a proprietary elbow with self-sealing valve that provides access to the patient’s mouth. ReddyPort™ Elbow, in combination with ReddyPort™ NIV Maintenance Kit, allows the ability to clean and moisturize the patient’s mouth without mask removal. Oral hygiene is proven to help reduce risk of infection and improve patient satisfaction.


Reference:


1 Rochwerg B, Brochard L, Elliott MW, Hess D, et al. Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure. Eur Respir J. 2017: 31;50(2):1602426.

SourceReddyPort
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy